RA Capital Management LP recently announced the acquisition of new stake in Vor Biopharma Inc. (NASDAQ:VOR). The institutional investor has increased its shareholding in the Healthcare company by 104.56% to 22.75 million shares with purchase of 11.63 million shares. This fresh investment now brings its stake to 34.65% valued currently at $151.28 million. In addition, Paradigm BioCapital Advisors LP raised its holdings by 0.62 million to 2.33 million shares. And Baker Bros. Advisors LP has lifted its position by 28.73% or 0.33 million shares – to 1.47 million shares.
With over 0.14 million Vor Biopharma Inc. (VOR) shares trading Tuesday and a closing price of $5.33 on the day, the dollar volume was approximately $0.74 million. The shares have shown a positive half year performance of 17.66% and its price on 01/24/23 lost nearly -3.27%. Currently, there are 38.01M common shares owned by the public and among those 34.33M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 11,962,407 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Vor Biopharma Inc. are Vanguard Total Stock Market Index, Fidelity Select Port. – Biotechno, and Fidelity Capital Appreciation Fun. Vanguard Total Stock Market Index owns 0.99 million shares of the company’s stock, all valued at over $6.58 million. The company bought an additional 0.5 million shares recently to bring their total holdings to about 1.51% of the shares outstanding. Fidelity Capital Appreciation Fun now owns shares totaling to 0.56% of the shares outstanding.
Shares of Vor Biopharma Inc. (NASDAQ: VOR) opened at $5.50, down -$0.01 from a prior closing price of $5.51. However, the script later moved the day high at 5.60, down -3.27%. The company’s stock has a 5-day price change of -12.05% and 29.37% over the past three months. VOR shares are trading -19.85% year to date (YTD), with the 12-month market performance down to -36.55% lower. It has a 12-month low price of $3.48 and touched a high of $9.72 over the same period. VOR has an average intraday trading volume of 194.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.60%, -5.93%, and 5.63% respectively.
Institutional ownership of Vor Biopharma Inc. (NASDAQ: VOR) shares accounts for 48.50% of the company’s 38.01M shares outstanding. Mutual fund holders own 47.46%, while other institutional holders and individual stakeholders account for 6.79% and 27.84% respectively.
It has a market capitalization of $337.02M. The earnings-per-share (ttm) stands at -$2.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.18% over the week and 8.98% over the month.
Analysts forecast that Vor Biopharma Inc. (VOR) will achieve an EPS of -$0.61 for the current quarter, -$0.6 for the next quarter and -$2.36 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.7 while analysts give the company a high EPS estimate of -$0.57. Comparatively, EPS for the current quarter was -$0.5 a year ago. Earnings per share for the fiscal year are expected to decrease by -51.80%, and 5.10% over the next financial year.
Looking at the support for the VOR, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on July 26, 2022, with the firm’s price target at $18. Goldman coverage for the Vor Biopharma Inc. (VOR) stock in a research note released on April 27, 2022 offered a Neutral rating with a price target of $6. H.C. Wainwright was of a view on December 17, 2021 that the stock is Buy, while Robert W. Baird gave the stock Outperform rating on December 03, 2021, issuing a price target of $38. Oppenheimer on their part issued Outperform rating on December 02, 2021.
